He sold Neuvax to GALE for $7 million.
If this were the $billion per year blockbuster that the DreamTeam, dopeindenver and ourpoliticianssucks want you to believe it is, then why was it sold for only $7 million and no big pharma were interested.
You don't think Apthera was shopped to the highest bidder?
According to the founder "we found a subset of women who had not recurred, these were women with low and intermediate levels of HER2 expression. This observation was not obvious and thus we submitted patents on this very unusual observation, and the claims of this patent were just granted."
So, Apthera had a drug for a cherry picked subgroup with a patent limited to that subgroup, The general Neuvax patent expires in 2015. It's surprising that anyone would buy this drug and spend money developing it in trials that are sure to fail. But Apthera found a sucker. Perhaps Ahn just wanted a low priced drug that he could pump to gullible saps and didn't care that it will fail. He could have the DreamTeam pump the "science" (how blatantly ludicrous is that?) of a failed drug based on data mining,
INO was overpriced $900M and it's still overpriced at $400M and it will be overpriced at $100M.
There's nothing here but hype, and hype is worthless.
Why has Inovio not completed even one Phase 3 trial?
Why have all the partners terminated the agreements?
The answer to both questions is the same: Inovio has nothing that works.
AMRN was PUMPED on every board.
The DUMP will produce an equally dramatic plunge.
$3.33 to $2.85 is just the start.
FDA approval expected any day.
The Hep C market is huge.
Some 60M pap mer tests are taken annually in the US.
GTHP's biophothonic scan is noninvasive, more accurate and produces instant test results.
Profit margins on the disposable used in each scan are 90%.
It's already approved in EU, Canada, Mexico.
International sales are ramping up.
Kim took over in 2009. Some 40M shares were outstanding then. By 2014, the count swelled to 240M.
It's hard to discern what necessitated all the dilution. Perhaps it was the expense of the whirl wind world conference tours that Kim has been on.
In any event a second 1 for 4 reverse split was enacted by Kim after running up the share count.
after the exercise of 2,000,000 more options at .015
GTHP developed a biophothonic cervical cancer scan.
It's noninvasive, more accurate than pap smears and the test results are immediate.
Some 60M pap smear tests are taken in the US.
The market is huge.
"For submissions that do not require Advisory Committee input, FDA will issue a MDUFA decision within 180 FDA Days for: 70% of submissions received in FY 2013; 80% of submissions received in FY 2014 and FY 2015; and 90% of submissions received in FY 2016 and FY 2017."
(I guess we're in the 20% of filers.)
"For all PMA submissions that do not reach a MDUFA decision by 20 days after the applicable FDA Day goal, FDA will provide written feedback to the applicant to be discussed in a meeting or teleconference, including all outstanding issues with the application preventing FDA from reaching a decision. The information provided will reflect appropriate management input and approval, and will include action items for FDA and/or the applicant, as appropriate, with an estimated date of completion for each party to complete their respective tasks. Issues should be resolved through interactive review. If all of the outstanding issues are adequately presented through written correspondence, FDA and the applicant can agree that a meeting or teleconference is not necessary."
(If the MDUFA is not received by Feb 20th, there's a problem.)
"FDA will issue a MDUFA decision within 180 FDA Days for: 85% of submissions received in FY 2013; 90% of submissions received in FY 2014 and FY 2015; and 95% of submissions received in FY 2016 through FY 2017."
(We're in the 10%.)
It's an excellent time to sell.
The dwarfing of your account continues.
Apple and Microsoft were founded in 1975 and 1976.
What are their accumulated revenues and profits since then?
So what? Somebody has to own the stock. Index funds hold a large chunk because they have to.
This is a diversion from Inovio's accomplishments, or lack there of.
TYPICAL: a biotech complete late stage trials and submits a NDA.
ATYPICAL: endless mice studies
ATYPICAL: completing a P2 trial but never starting a P3 trial.
ATYPICAL: hyping a vaccine for ebola but never starting a trial
ATYPICAL: peddling a technology that failed decades ago instead of writing it off.
$200.00 to $6.45 and two reverse splits is an unmitigated disaster.
So Pearson sold short before his hit piece and the covered and went long.
Then cohort AF came out with puff piece and Perarson sold and went short again.
The inverse Pump & Dump is now a traditional Pump & Dump?
The manipulation is astounding!
Investors will be working in the dark, taking a leap of faith.
Patience is a virtue if it doesn't take an eternity.
Lots of baggies died here waiting for just one P3 trial.
Why is it that other biotechs which were founded after INO have loads of approved drugs and Kim is still peddling mice studies?